Kano Therapeutics

Biotechnology · Cambridge, MA · Founded 2021 · Privately Held (backing)

Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. Kano Therapeutics is based in Cambridge, MA and was founded in 2021. It was valued at $15 million at its seed round in Aug 2024, the last priced event on record. It has raised $7.4 million across 2 recorded rounds; the latest was a $5 million seed round in Aug 2024.

PMV mark · valuation
$15.0M
Oct 2026
Priced at
its seed round
Aug 2024
Total raised
$7.4M
Last round
Seed Round
Aug 2024

Who backs Kano Therapeutics?

12 investors
InvestorType
Metaplanet HoldingsVenture capital
Activate Global—
Engine VenturesVenture capital
ZAKA VCVenture capital
VSquared VenturesVenture capital
Launchpad Venture GroupAngel
Amino Collective—
MIT Sloan Healthcare and BioInnovations Conference—
MIT Sloan School of Management—
Nucleate—
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Kano Therapeutics investors

12 investors are on record for Kano Therapeutics, including Metaplanet Holdings, Activate Global, Engine Ventures and ZAKA VC. By type, the record holds 4 venture capital firms and 1 angel investor. The seed round in Aug 2024 drew 4 investors.

Free account
More of Kano Therapeutics with a free account
  • ·The complete investor list: 12 names
  • ·Watch Kano Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like Kano Therapeutics in biotechnology. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View